BAN2401 slows AD progression at 18 months

Biogen Inc. (NASDAQ:BIIB) gained $58.67 (20%) to $357.48 on Friday, adding about $12.3 billion in market cap, on new data for its Alzheimer's disease candidate BAN2401. Biogen and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary endpoint data late Thursday showing that the highest dose of BAN2401 significantly slowed disease

Read the full 494 word article

User Sign In